Patients Who Receive Thoracic Irradiation
Conditions
Brief summary
The purpose of this study is to investigate the risk factors and mechanisms of cardiotoxicity following thoracic radiotherapy and to provide insights in preventing radiation-related cardiotoxicity. -Condition or disease : Thoracic irradiation -Intervention/treatment : Cardiac evaluation, Blood sampling
Detailed description
Cancer patients who undergo thoracic irradiation receive a certain amount of dose to the heart. Cardiotoxicity may occur in some patients several years after radiotherapy due to the late effect of radiation. Considering that cardiotoxicity is often lethal, screening and preventing radiation-induced cardiotoxicity is crucial in patients receiving thoracic irradiation. Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation. The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed. Among the patients who developed cardiotoxicity, blood sampling will be performed to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets.
Interventions
PROCEDURECardiac evaluation and blood sampling
Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation. The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed. The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets.
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with solid cancer who are subject to thoracic irradiation. 2. Patients who are 20 years old or older 3. Eastern Cooperative Oncology Group Performance Status Scale 0-2 4. Patients with cognitive abilities to receive virtual reality information
Exclusion criteria
1. Patients with a history of previous thoracic irradiation 2. Patients who refused consent 3. Patients with a history of heart failure before radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiotoxicity rate | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 2 years |
| Cancer-specific survival | 2 years |
| Progression-free survival | 2 years |
| Other toxicity rates | 2 years |
Countries
South Korea
Contacts
Primary ContactHong In Yoon
Outcome results
None listed